Overlap of ILAR and Preliminary PRINTO Classification Criteria for Non-Systemic Juvenile Idiopathic Arthritis in an Established UK Cohort: Results from the Childhood Arthritis Prospective Study

Juvenile Idiopathic Arthritis

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

Arthritis Care Res (Hoboken).

Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, Rygg M, Toftedal P, Nielsen S, Fasth A, Berntson L, Nordal E, Herlin T, Nordic Study Group of Pediatric Rheumatology (NoSPeR)

doi: 10.1002/acr.23853.

Autoimmune DiseaseJuvenile Idiopathic Arthritis

Early feeding and risk of Juvenile idiopathic arthritis: a case control study in a prospective birth cohort

Pediatr Rheumatol Online J.

Kindgren E, Fredrikson M, Ludvigsson J

doi: 10.1186/s12969-017-0175-z.

PsoriasisJuvenile Idiopathic ArthritisPsoriatic Arthritis

Psoriasis and associated variables in classification and outcome of juvenile idiopathic arthritis - an eight-year follow-up study

Pediatr Rheumatol Online J.

Ekelund M, Aalto K, Fasth A, Herlin T, Nielsen S, Nordal E, Peltoniemi S, Rygg M, Zak M, Berntson L; Nordic Study Group of Pediatric Rheumatology (NoSPeR)

doi: 10.1186/s12969-017-0145-5.

Juvenile Idiopathic Arthritis

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Ann Rheum Dis.

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ

doi: 10.1136/annrheumdis-2018-213150.

Juvenile Idiopathic Arthritis

Treat-to-target using first-line recombinant interleukin-1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study

Arthritis Rheumatol.

Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, de Jager W, de Groot MCH, Haitjema S, Holzinger D, Foell D, van Loosdregt J, Wulffraat NM, de Roock S, Vastert SJ

doi: 10.1002/art.40865.

Juvenile Idiopathic Arthritis

Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis: part 1-results of the Canadian model in the Nordic cohort

Arthritis Res Ther.

Rypdal V, Guzman J, Henrey A, Loughin T, Glerup M, Arnstad ED, Aalto K, Rygg M, Nielsen S, Herlin T, Fasth A, Berntson L, Rypdal M, Nordal E, ReACCh-Out and NoSPeR Investigators.

doi: 10.1186/s13075-019-2060-2.

Juvenile Idiopathic Arthritis

Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open-label, Randomized Phase IIIb/IV Study

Arthritis Rheumatol.

Quartier P, Alexeeva E, Tamàs C, Chasnyk V, Wulffraat N, Palmblad K, Wouters C, Brunner H, Marzan K, Schneider R, Horneff G, Martini A, Anton J, Wei X, Slade A, Ruperto N, Abrams K, Pediatric Rheumatology International Trials Organization (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG)

doi: 10.1002/art.41488.

Juvenile Idiopathic Arthritis

Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort

Arthritis Res Ther.

Henrey A, Rypdal V, Rypdal M, Loughin T, Nordal E, Guzman J, ReACCh-Out and NoSPeR Investigators.

doi: 10.1186/s13075-019-2091-8.

Systemic Lupus Erythematosus

Impact of the new 2019 EULAR/ACR classification criteria for Systemic Lupus Erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease

Arthritis Care Res (Hoboken).

Radin M, Schreiber K, Cecchi I, Bortoluzzi A, Crisafulli F, de Freitas CM, Bacco B, Rubini E, Foddai SG, Padovan M, Gallo Cassarino S, Franceschini F, Andrade D, Benedetto C, Govoni M, Bertero T, Marozio L, Roccatello D, Andreoli L, Sciascia S

doi: 10.1002/acr.24391.

Related content

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

Early feeding and risk of Juvenile idiopathic arthritis: a case control study in a prospective birth cohort

Psoriasis and associated variables in classification and outcome of juvenile idiopathic arthritis - an eight-year follow-up study

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Treat-to-target using first-line recombinant interleukin-1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study

Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis: part 1-results of the Canadian model in the Nordic cohort

Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open-label, Randomized Phase IIIb/IV Study

Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort

Impact of the new 2019 EULAR/ACR classification criteria for Systemic Lupus Erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease